A Phase 2 interventional study of VYD2311 and Placebo in Long COVID, COVID-19 (SARS-CoV-2 Infection) and COVID 19 Vaccine, sponsored by Invivyd, Inc.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Invivyd, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your body handles them), pharmacokinetics (PK) (how a drug is taken into your body, spread throughout, broken down, and eliminated), clinical activity (does the drug make patients feel better), immunogenicity (how the immune system responds to the drug), and serum virus neutralizing antibody response (antibodies that block a virus from infecting cells) of VYD2311, the investigational monoclonal antibody being studied, in adults with Long-COVID or Post-Vaccination Syndrome.
Participants will receive an intravenous (IV) infusion on Day 1 of either the investigational drug or placebo followed by two intramuscular (IM) injections (a shot in the upper arm), one on day 30 and the other on Day 60. The IM injections will also either be investigational drug or placebo. The participants will be then asked to complete a 30-day follow up period and end the study on day 90.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's planned enrollment of 130 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Invivyd, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Post-Vaccination Syndrome (PVS) Cohort: Administered at least a single dose of a SARS-CoV-2 vaccine prior to the onset of symptoms resulting in diagnosis of PVS.
3. Clinical evidence of at least 2 new or worsening LC or PVS symptoms with at least 1 symptom considered grade 3 or greater in severity which: (i) LC Cohort - presented between 6 and 24 months after inciting acute COVID-19 infection.
(ii) PVS Cohort - presented and persisted after administration of a COVID-19 vaccine.
(iii) are not primarily attributable to a pre-existing condition or alternative diagnosis confirmed by the investigator during screening: chest pain, diarrhea, abdominal pain, nausea, loss of smell or taste, palpitations, shortness of breath, cough, sleep apnea, swelling of legs, weakness, muscle pain, joint pain, back pain, foot pain, abnormal movements, tremor, headache, sleep disturbance, difficulty with memory/concentration ("brain fog"), fatigue, post-exertional malaise.
Exclusion Criteria:
Has been treated with or anticipates being treated during the study period with any of the following medications:
NOTE: The above information is not intended to contain all considerations relevant to a participant's potential eligibility in the clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311
Drug: VYD2311
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with Placebo - 0.9% sodium chloride (normal saline)
Drug: Placebo
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with placebo (normal saline)
Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90
Time frame: 90 days
Serum concentrations of VYD2311 through Day 90
Time frame: 90 days
Change in score of the PROMIS-29+2 from baseline through Day 90
Time frame: 90 days
Change in score of the PCFS from baseline through Day 90
Time frame: 90 days
Change in score of the PGI-C from baseline through Day 90
Time frame: 90 days
Change in score of the PGI-S from baseline through Day 90
Time frame: 90 days
Change in score of the SDMT from baseline through Day 90
Time frame: 90 days
Incidence of ADAs against VYD2311 through Day 90
Time frame: 90 days
sVNA titers (VYD2311 serum concentration/variant IC50) against relevant SARS-CoV-2 variants through Day 90
Time frame: 90 days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibramvibart
Post-Acute COVID-19 Syndrome →
Invivyd, Inc.